About this study
This study is for patients with newly diagnosed Wilms tumors that are called “favorable histology” based on the way they look under a microscope. Treatment for these patients may include surgery, chemotherapy, and sometimes radiation therapy.
In the past, some patients treated for this type of tumor had their cancer return after treatment (relapse), and some patients may develop late effects from their treatment.
This clinical trial will test a new way to identify patients who may have a higher risk of relapse and adjust their treatment based on their risk. We also want to find out if this will reduce the number of late effects.
We will use several ways to identify new patients who are at high risk for relapse. These include looking at:
- Genetic changes to the DNA in their cancer cells
- How they respond to chemotherapy
- How their tumor tissue looks under the microscope after surgery
- Whether the disease has spread to other areas (metastasis)
We will use this information to help guide treatment.
There will be 6 different chemotherapy treatment groups. Based on their risk of relapse, patients will be put into 1 of these groups to get medicine to help fight cancer cells. Some patients who have tumors that are at very low risk of relapse may be treated with surgery alone.
Eligibility overview
- Enrolled in APEC14B1
- Stage I–IV favorable histology Wilms tumor
- Up to age 30